---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274703713.md"
description: "Prelude Therapeutics shares are trading higher after the company announced the FDA clearance to proceed with a Phase 1 study under its IND for PRT12396, a mutant-selective JAK2V617F inhibitor."
datetime: "2026-02-03T19:28:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274703713.md)
  - [en](https://longbridge.com/en/news/274703713.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274703713.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274703713.md) | [繁體中文](https://longbridge.com/zh-HK/news/274703713.md)


# 

Prelude Therapeutics shares are trading higher after the company announced the FDA clearance to proceed with a Phase 1 study under its IND for PRT12396, a mutant-selective JAK2V617F inhibitor.

### Related Stocks

- [Prelude Therapeutics Incorporated (PRLD.US)](https://longbridge.com/en/quote/PRLD.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)
- [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/en/news/281174396.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md)